King Of Vaccines Protecting Children From Birth Onwards
Bio Spectrum|April 2021
Son of a horse breeder, Cyrus Poonawalla founded Serum Institute of India (SII) in 1966 in Pune when he was just 22 years and got married to Villoo. Over the years, his passion of offering affordable vaccines to the world has motivated to build SII into one of the world’s largest vaccine makers.

DR Cyrus Poonawalla- CHAIRPERSON, Serum Institute of India

SII now produces 1.5 billion doses of a range of vaccines annually, including for measles, polio, and flu. With sales revenue of over Rs 5000 crore, Serum Institute of India is ranked as India’s No. 1 biotechnology company, manufacturing highly specialized life-saving biologicals using cutting edge genetic and cell-based technologies, antisera, and other medical specialties.

THE JOURNEY OF SERUM INSTITUTE

Continue reading your story on the app

Continue reading your story in the magazine

MORE STORIES FROM BIO SPECTRUMView All

Rare diseases policy outlines challenges sans solutions

There is no substantial data on the number of people suffering from rare diseases in India and the data that is available is from tertiary care hospitals. The lack of epidemiological data on rare diseases makes it a herculean task to determine the prevalence and burden of rare diseases, hence hampering the definition of rare diseases in the Indian context.

9 mins read
Bio Spectrum
June 2021

PSA launches community mental-health digital platform

The Principal Scientific Adviser (PSA) to the Government of India Prof. K VijayRaghavan has virtually launched ‘MANAS’ App to promote wellbeing across age groups.

1 min read
Bio Spectrum
June 2021

“India should have a vibrant clinical research community who can advise drug developers”

The Indian Society for Clinical Research (ISCR), an association of clinical research professionals, has announced the appointment of Dr Sanish Davis as its President for the term 202123.

5 mins read
Bio Spectrum
June 2021

MALARIA DENGUE TB PLAY SECOND FIDDLE to COVID - 19

Although India has worked relentlessly towards developing innovative testing solutions for COVID-19 throughout last year, the timely detection of a number of other infectious diseases has been sidelined. In India, the range and burden of infectious diseases such as tuberculosis, malaria, filariasis, leprosy, HIV infection, typhoid, hepatitis etc., are enormous. In fact, inadequate containment of the vector has resulted in recurrent outbreaks of dengue fever and re-emergence of chikungunya virus disease and typhus fever. If India can develop more than 20 different diagnostic tests or devices in a single year to fight COVID-19, many more such innovations can be brought to effectively detect other infections looming in our country.

10+ mins read
Bio Spectrum
June 2021

Govt fast-tracks emergency approvals for foreign-made COVID-19 vaccines

The matter of augmenting the basket of vaccines available for fighting the pandemic as well as accelerating the pace and coverage of domestic vaccination programmes was discussed recently at the 23rd meeting of the National Expert Group on Vaccine Administration for COVID-19 (NEGVAC).

1 min read
Bio Spectrum
June 2021

Wipro Focuses On Transforming Vaccine Safety Assessment

Bengaluru -based IT firm Wipro has announced a partnership with Hyderabad-based Transcell Oncologics to transform vaccine safety assessment using augmented intelligence (AI).

1 min read
Bio Spectrum
June 2021

Dr. Reddy's Launches Sputnik V Vaccine In India

Dr. Reddy’s Laboratories announced that the first consignment of imported doses of the Sputnik V vaccine that landed in India on May 1, 2021, received regulatory clearance from the Central Drugs Laboratory, Kasauli, on May 13, 2021. As part of a limited pilot, the soft launch of the vaccine has commenced and the first dose of the vaccine was administered in Hyderabad on May 14, 2021.

1 min read
Bio Spectrum
June 2021

“Made in India products need an ecosystem for commercialisation of innovations”

Established in 1998, Ernakulam-based Agappe Diagnostics is one of the rapidly growing companies in the in vitro diagnostic (IVD) industry in India, having a wide range of products in the pre-analytical and analytical segment. Focused on research, design, and production of clinical chemistry reagents and instrument, Agappe has over 1000 distributors and holds a significant place in the global original equipment manufacturer (OEM) business. The company currently has a workforce of more than 600 employees spread across sectors such as R&D, manufacturing, sales, support and operations. In conversation with BioSpectrum, Thomas John, Managing Director, Agappe Diagnostics, Ernakulam shares his strategies and plans for the company’s growth in the long run.

4 mins read
Bio Spectrum
May 2021

Vocalising pain is a must

Women have unique health issues. In fact, some of the health issues that affect both men and women can affect women very differently.

3 mins read
Bio Spectrum
May 2021

“India should focus on innovating drugs and molecules to emerge as a global leader”

The Organisation of Pharmaceutical Producers of India (OPPI) has elected S Sridhar as its next President for a period of two years, effective from February 15, 2021. He takes over from Sharad Tyagi, Former Managing Director, Boehringer Ingelheim India Pvt Ltd. Sridhar is currently serving as the Managing Director of Pfizer Limited and is heading Pfizer Inc’s commercial business in India. Sridhar has been a member of the Executive Committee of OPPI for the past six years and has also chaired its Finance and Taxation Work Group. He is a strong voice of healthcare transformation in the country and was the chair of FICCI’s Pharma Committee till recently. In conversation with BioSpectrum, S Sridhar talks about making a difference to patients, the industry and the country via this new role.

2 mins read
Bio Spectrum
May 2021